{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:31:49Z","timestamp":1790775109848,"version":"4.1.0"},"reference-count":177,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2025.04.024","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T11:51:09Z","timestamp":1745063469000},"page":"2527-2547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gene-based therapies for steatotic liver disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Viktoriia","family":"Iakovleva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ype P.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.04.024_bib1","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study","volume":"362","author":"Tapper","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2025.04.024_bib2","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/hep.32032","article-title":"NAFLD and alcohol-associated liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040","volume":"74","author":"Flemming","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/HEP.0000000000000899","article-title":"Alcohol-associated liver disease-Global epidemiology","volume":"80","author":"\u00c5berg","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019","volume":"3","author":"Wong","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ymthe.2025.04.024_bib8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The global burden of liver disease","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2025.04.024_bib10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/hum.2022.169","article-title":"Liver Gene Therapy","volume":"33","author":"Nathwani","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.024_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2019.04.002","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases","volume":"127","author":"Ferreira","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.04.024_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.04.024_bib14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib15","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","article-title":"Pathological features of fatty liver disease","volume":"147","author":"Yeh","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib24","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: Pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2025.04.024_bib25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.024_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.04.024_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib28","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jhep.2022.12.008","article-title":"Liver transplant for alcohol-associated liver disease continues to rise 2 years into the COVID-19 pandemic especially among young adults","volume":"78","author":"Lee","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/TP.0000000000002843","article-title":"Gender disparities in patients with alcoholic liver disease evaluated for liver transplantation","volume":"104","author":"McElroy","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2025.04.024_bib30","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1111\/acer.14968","article-title":"All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank","volume":"46","author":"Whitfield","year":"2022","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.ymthe.2025.04.024_bib31","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1038\/s41467-023-43064-x","article-title":"Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease","volume":"14","author":"Ding","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/apt.17958","article-title":"Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population","volume":"59","author":"Schneider","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.024_bib34","series-title":"A Turning Point in Hepatology? EASL Reflects on the First Approved Drug for MASH","author":"Francque","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.024_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib36","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib37","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib38","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","article-title":"National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.04.024_bib39","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/oby.2009.4","article-title":"Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort","volume":"17","author":"Wagenknecht","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ymthe.2025.04.024_bib40","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/hep.26440","article-title":"Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent","volume":"58","author":"Palmer","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib41","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1053\/j.gastro.2009.01.050","article-title":"Heritability of nonalcoholic fatty liver disease","volume":"136","author":"Schwimmer","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.28674","article-title":"Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study","volume":"64","author":"Cui","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib43","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study","volume":"149","author":"Loomba","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/liv.15533","article-title":"PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review","volume":"43","author":"Boeckmans","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2025.04.024_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111321","article-title":"Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice","volume":"40","author":"Kabbani","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.04.024_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng.488","article-title":"Variant in PNPLA3 is associated with alcoholic liver disease","volume":"42","author":"Tian","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib47","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","article-title":"Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease","volume":"55","author":"Chen","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib48","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","article-title":"A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation","volume":"54","author":"Vujkovic","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib49","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","article-title":"Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease","volume":"76","author":"Luukkonen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib50","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/hep4.1751","article-title":"Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort","volume":"5","author":"Wang","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.gastro.2018.03.038","article-title":"Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease","volume":"155","author":"Ma","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib52","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","article-title":"A human liver cell atlas reveals heterogeneity and epithelial progenitors","volume":"572","author":"Aizarani","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.04.024_bib54","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"Bruschi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib56","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.cgh.2022.12.025","article-title":"Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic\/Latino Individuals of Diverse Genetic Ancestries","volume":"21","author":"Rutledge","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16123","article-title":"Global Epidemiological Impact of PNPLA3 I148M on Liver Disease","volume":"45","author":"Kozlitina","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2025.04.024_bib58","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.aohep.2018.10.004","article-title":"Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population","volume":"18","author":"Mazo","year":"2019","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib59","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1159\/000521062","article-title":"The risk of cirrhosis and its complications based on PNPLA3 rs738409 G allele frequency","volume":"40","author":"Shao","year":"2022","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ymthe.2025.04.024_bib61","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","article-title":"PNPLA3 I148M polymorphism and progressive liver disease","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib63","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.34221","article-title":"Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ymthe.2025.04.024_bib64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib65","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027087","article-title":"The PNPLA3 rs738409 148M\/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis","volume":"6","author":"Nischalke","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.04.024_bib67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.12998\/wjcc.v6.i10.355","article-title":"PNPLA3 rs139051 is associated with phospholipid metabolite profile and hepatic inflammation in nonalcoholic fatty liver disease","volume":"6","author":"Luo","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.ymthe.2025.04.024_bib68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.18632\/aging.101067","article-title":"Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans","volume":"9","author":"Liu","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ymthe.2025.04.024_bib69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12916-019-1364-z","article-title":"GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network","volume":"17","author":"Namjou","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib70","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymthe.2025.04.024_bib71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.28370","article-title":"The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage","volume":"63","author":"Donati","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib72","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","article-title":"A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis","volume":"285","author":"He","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.04.024_bib73","doi-asserted-by":"crossref","first-page":"37085","DOI":"10.1074\/jbc.M111.290114","article-title":"Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease","volume":"286","author":"Huang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.04.024_bib74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1194\/jlr.M011205","article-title":"Pnpla3\/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome","volume":"52","author":"Basantani","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymthe.2025.04.024_bib75","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/hep.23812","article-title":"Patatin-like phospholipase domain-containing 3\/adiponutrin deficiency in mice is not associated with fatty liver disease","volume":"52","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib76","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1172\/JCI65179","article-title":"Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis","volume":"122","author":"Li","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.04.024_bib77","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.31609","article-title":"Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis","volume":"73","author":"Banini","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib78","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis","volume":"82","author":"Wang","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib80","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s42255-019-0066-3","article-title":"Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes","volume":"1","author":"Yang","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ymthe.2025.04.024_bib81","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1002\/hep.32063","article-title":"Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells","volume":"74","author":"Tilson","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib82","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","article-title":"Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis","volume":"41","author":"Hendriks","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib83","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ajg.2015.137","article-title":"PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease","volume":"110","author":"Salameh","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib84","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014324","article-title":"Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis","volume":"98","author":"Dai","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ymthe.2025.04.024_bib85","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1073\/pnas.1410741111","article-title":"Comparative proteomic study reveals 17\u03b2-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease","volume":"111","author":"Su","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.024_bib86","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib87","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib88","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12876-021-02067-y","article-title":"Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis","volume":"21","author":"Tang","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib89","first-page":"8997","article-title":"HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"24","author":"Wang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2025.04.024_bib90","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/hep.31517","article-title":"Hsd17b13 Deficiency Does not Protect Mice From Obesogenic Diet Injury","volume":"73","author":"Ma","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib91","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nprot.2013.032","article-title":"Mouse model of chronic and binge ethanol feeding (the NIAAA model)","volume":"8","author":"Bertola","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2025.04.024_bib92","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ymthe.2025.04.024_bib93","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.17292","article-title":"the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD","volume":"57","author":"Amangurbanova","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.024_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008629","article-title":"A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease","volume":"16","author":"Emdin","year":"2020","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib96","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1053\/j.gastro.2020.06.014","article-title":"Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1","volume":"159","author":"Innes","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03521-3","article-title":"MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis","volume":"11","author":"Janik","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.04.024_bib98","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2020.04.021","article-title":"MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans","volume":"73","author":"Luukkonen","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib99","article-title":"Hepatocyte mARC1 promotes fatty liver disease","volume":"5","author":"Lewis","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.ymthe.2025.04.024_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1011179","article-title":"Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse","volume":"20","author":"Smagris","year":"2024","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107353","article-title":"Biochemical and functional characterization of the p. A165T missense variant of mitochondrial amidoxime-reducing component 1","volume":"300","author":"Hou","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.04.024_bib102","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/liv.15857","article-title":"Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome","volume":"44","author":"Dutta","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2025.04.024_bib103","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000419","article-title":"Liver-specific mitochondrial amidoxime\u2013reducing component 1 (Mtarc1) knockdown protects the liver from diet-induced MASH in multiple mouse models","volume":"8","author":"Guo","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib104","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MOL.0000000000000930","article-title":"Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism","volume":"35","author":"Liu","year":"2024","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib106","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1053\/j.gastro.2016.01.005","article-title":"Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice","volume":"150","author":"Fan","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib107","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.atherosclerosis.2017.11.033","article-title":"TM6SF2: A novel target for plasma lipid regulation","volume":"268","author":"Li","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ymthe.2025.04.024_bib108","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100234","article-title":"Membrane-bound O-acyltransferase 7 (MBOAT7)-driven phosphatidylinositol remodeling in advanced liver disease","volume":"63","author":"Varadharajan","year":"2022","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymthe.2025.04.024_bib110","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib111","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ajhg.2016.07.019","article-title":"Mutations in MBOAT7, Encoding Lysophosphatidylinositol Acyltransferase I, Lead to Intellectual Disability Accompanied by Epilepsy and Autistic Features","volume":"99","author":"Johansen","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib112","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ymthe.2025.04.024_bib113","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1142358","article-title":"Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels","volume":"316","author":"Saxena","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.04.024_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"Plos Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib115","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s11033-010-0212-1","article-title":"Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people","volume":"38","author":"Yang","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ymthe.2025.04.024_bib116","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db07-1807","article-title":"The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population","volume":"57","author":"Vaxillaire","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ymthe.2025.04.024_bib117","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101722","article-title":"The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326","volume":"72","author":"Ford","year":"2023","journal-title":"Mol. Metab."},{"key":"10.1016\/j.ymthe.2025.04.024_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3441","article-title":"Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator","volume":"11","author":"Vella","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116499","article-title":"Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants","volume":"229","author":"Ford","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib121","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib122","article-title":"A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes","author":"Saliba-Gustafsson","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib123","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-021-03974-6","article-title":"Convergent somatic mutations in metabolism genes in chronic liver disease","volume":"598","author":"Ng","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.04.024_bib124","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJMoa2117872","article-title":"Germline mutations in CIDEB and protection against liver disease","volume":"387","author":"Verweij","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3748\/wjg.v27.i1.1","article-title":"Experimental models of metabolic and alcoholic fatty liver disease","volume":"27","author":"Buyco","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib127","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/nm.4334","article-title":"Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4","volume":"23","author":"Zhao","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41467-023-37247-9","article-title":"Acute liver steatosis translationally controls the epigenetic regulator MIER1 to promote liver regeneration in a study with male mice","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/nu8010023","article-title":"Fatty Acid Desaturases, Polyunsaturated Fatty Acid Regulation, and Biotechnological Advances","volume":"8","author":"Lee","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.ymthe.2025.04.024_bib130","first-page":"1","article-title":"Liver DNA methylation of FADS2 associates with FADS2 genotypex","volume":"11","author":"Walle","year":"2019","journal-title":"Clin. epigenetics"},{"key":"10.1016\/j.ymthe.2025.04.024_bib131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41536-023-00337-9","article-title":"Mfap4: a promising target for enhanced liver regeneration and chronic liver disease treatment","volume":"8","author":"Iakovleva","year":"2023","journal-title":"NPJ Regen. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib132","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCGENETICS.110.958728","article-title":"A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease","volume":"4","author":"Wild","year":"2011","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib133","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.bbalip.2019.01.007","article-title":"Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation","volume":"1864","author":"Leopold","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ymthe.2025.04.024_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101165","article-title":"Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.04.024_bib135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ymthe.2024.11.016","article-title":"SNRK modulates mTOR-autophagy pathway for liver lipid homeostasis in MAFLD","volume":"33","author":"Lin","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.024_bib136","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.04.024_bib137","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.04.024_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102184","article-title":"Oligonucleotide therapies for nonalcoholic steatohepatitis","volume":"35","author":"Li","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.024_bib139","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.04.024_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib141","unstructured":"AstraZeneca (2023). Clinical Trial NCT05809934 \u201cA Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)\u201d https:\/\/clinicaltrials.gov\/study\/NCT05809934."},{"key":"10.1016\/j.ymthe.2025.04.024_bib143","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib151","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib152","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib153","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.ymthe.2025.04.024_bib154","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib155","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib156","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s42255-023-00775-1","article-title":"A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures","volume":"5","author":"Govaere","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ymthe.2025.04.024_bib157","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.09.026","article-title":"ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD","volume":"76","author":"Corey","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib158","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.024_bib159","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib160","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib161","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","article-title":"VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients","volume":"10","author":"Horie","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.04.024_bib162","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-024-02523-6","article-title":"AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion","author":"Kim","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib163","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/s41467-025-57382-9","article-title":"Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes","volume":"16","author":"Ferriero","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib164","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design","volume":"77","author":"Allen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib166","author":"Iakovleva"},{"key":"10.1016\/j.ymthe.2025.04.024_bib167","author":"Iakovleva"},{"key":"10.1016\/j.ymthe.2025.04.024_bib168","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.024_bib169","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/hbsn.2019.10.35","article-title":"PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver","volume":"9","author":"Yuan","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.ymthe.2025.04.024_bib170","article-title":"HSD17B13: a potential therapeutic target for NAFLD","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymthe.2025.04.024_bib171","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib172","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOL.0000000000000155","article-title":"Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism","volume":"26","author":"Raimondo","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ymthe.2025.04.024_bib173","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","year":"2014","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib174","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1038\/ncomms5871","article-title":"A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans","volume":"5","author":"Timpson","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib175","article-title":"An APOC3 3\u2032 UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site","volume":"6","author":"Hu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.04.024_bib176","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.024_bib177","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib178","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.04.024_bib179","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2025.04.024_bib180","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/liv.15283","article-title":"A minority of somatically mutated genes in pre-existing fatty liver disease have prognostic importance in the development of NAFLD","volume":"42","author":"Mann","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2025.04.024_bib181","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s42255-021-00518-0","article-title":"PSD3 downregulation confers protection against fatty liver disease","volume":"4","author":"Mancina","year":"2022","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ymthe.2025.04.024_bib182","article-title":"Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease","volume":"5","author":"Grove","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.ymthe.2025.04.024_bib183","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.04.024_bib184","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/s41467-020-15623-z","article-title":"Partial impairment of insulin receptor expression mimics fasting to prevent diet-induced fatty liver disease","volume":"11","author":"Merry","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.024_bib185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jhep.2020.03.032","article-title":"Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis","volume":"73","author":"Parisinos","year":"2020","journal-title":"J. Hepatol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:04:42Z","timestamp":1759611882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":177,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525001625002989"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.024","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene-based therapies for steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}